Neonatal and pediatric blood bank practice in the United States: Results from the AABB pediatric transfusion medicine subsection survey.
blood bank
neonatal
pediatric
plasma
platelets
red blood cells
transfusion
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
05
02
2021
received:
04
08
2020
accepted:
21
04
2021
pubmed:
11
6
2021
medline:
20
8
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
There are limited standards guiding the selection and processing of blood components specific for neonatal and pediatric transfusions. Therefore, blood banks (BBs) and transfusion services must create their own policies and procedures. The American Association of Blood Banks (AABB) Pediatric Transfusion Medicine Subsection Committee developed a 74-question survey to capture neonatal and pediatric BB practices in the United States. Thirty-five centers completed the survey: a response rate 15.8%. Responses indicated that most carry a mixed inventory of red blood cells (RBCs); 94.2% allow more than one type of RBC product for small-volume (SV) and large-volume (LV) transfusions to neonatal and pediatric patients. Many had storage age thresholds for RBCs transfused to neonates (SV = 60%, LV = 67.7%) but not older pediatric patients. The use of Group O for nonurgent RBC transfusion in neonates was common (74.2%). Responses related to special processing of RBCs and platelets indicated that 100% RBC and platelets are leukocyte-reduced (LR) for neonates and 97% for non-neonates. Irradiation of RBCs and platelets was commonly performed for neonatal transfusion (88.6%). Providing cytomegalovirus (CMV) seronegative products, volume reduction, and washing were variable. All centers transfused single-donor apheresis platelets; 20% allowed pathogen reduction (PR). The majority of centers have strategies limiting the amount of incompatible plasma transfused; however, few titrate ABO isoagglutinins in plasma-containing products (20% for platelets and 9.1% for plasma). Variability exists in BB practice for neonatal and pediatric transfusion. Future studies are needed to understand and define best BB practices in these patient populations.
Sections du résumé
BACKGROUND
There are limited standards guiding the selection and processing of blood components specific for neonatal and pediatric transfusions. Therefore, blood banks (BBs) and transfusion services must create their own policies and procedures.
STUDY DESIGN AND METHODS
The American Association of Blood Banks (AABB) Pediatric Transfusion Medicine Subsection Committee developed a 74-question survey to capture neonatal and pediatric BB practices in the United States.
RESULTS
Thirty-five centers completed the survey: a response rate 15.8%. Responses indicated that most carry a mixed inventory of red blood cells (RBCs); 94.2% allow more than one type of RBC product for small-volume (SV) and large-volume (LV) transfusions to neonatal and pediatric patients. Many had storage age thresholds for RBCs transfused to neonates (SV = 60%, LV = 67.7%) but not older pediatric patients. The use of Group O for nonurgent RBC transfusion in neonates was common (74.2%). Responses related to special processing of RBCs and platelets indicated that 100% RBC and platelets are leukocyte-reduced (LR) for neonates and 97% for non-neonates. Irradiation of RBCs and platelets was commonly performed for neonatal transfusion (88.6%). Providing cytomegalovirus (CMV) seronegative products, volume reduction, and washing were variable. All centers transfused single-donor apheresis platelets; 20% allowed pathogen reduction (PR). The majority of centers have strategies limiting the amount of incompatible plasma transfused; however, few titrate ABO isoagglutinins in plasma-containing products (20% for platelets and 9.1% for plasma).
CONCLUSIONS
Variability exists in BB practice for neonatal and pediatric transfusion. Future studies are needed to understand and define best BB practices in these patient populations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2265-2276Informations de copyright
© 2021 AABB.
Références
Sapiano MRP, Savinkina AA, Ellingson KD, Haass KA, Baker ML, Henry RA, et al. Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015. Transfusion. 2017;57(Suppl 2):1599-624.
Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung KW, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(Suppl 2):1588-98.
Rajbhandary S, Whitaker BI, Perez GE. The 2014-2015 AABB Blood Collection and Utilization Survey Report. 2018. http://www.aabb.org/research/hemovigilance/bloodsurvey/Docs/2014-2015-AABB-Blood-Survey-Report.pdf; last accessed July 31, 2020.
Patel RM, Meyer EK, Widness JA. Research opportunities to improve neonatal red blood cell transfusion. Transfus Med Rev. 2016;30:165-73.
Fung MK, Roseff SD, Vermoch KL. Blood component preferences of transfusion services supporting infant transfusions: a University HealthSystem Consortium benchmarking study. Transfusion. 2010;50:1921-5.
Spinella PC, Dressler A, Tucci M, Carroll CL, Rosen RS, Hume H, et al. Survey of transfusion policies at US and Canadian children's hospitals in 2008 and 2009. Transfusion. 2010;50:2328-35.
Fergusson DA, Hebert P, Hogan DL, LeBel L, Rouvinez-Bouali N, Smyth JA, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308:1443-51.
Spinella PC, Tucci M, Fergusson DA, Lacroix J, Hébert PC, Leteurtre S, et al. Effect of fresh vs standard-issue red blood cell transfusions on multiple organ dysfunction syndrome in critically ill pediatric patients: a randomized clinical trial. JAMA. 2019;322:2179-90.
Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014;168:1054-62.
Delaney M, Mayock D, Knezevic A, Norby-Slycord C, Kleine E, Patel R, et al. Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy. Transfusion. 2016;56:1945-50.
Cure P, Bembea M, Chou S, Doctor A, Eder A, Hendrickson J, et al. 2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine. Transfusion. 2017;57:1568-81.
Patel RM, Josephson C. Neonatal and pediatric platelet transfusions: current concepts and controversies. Curr Opin Hematol. 2019;26:466-72.
Standards for blood banks and transfusion services. 32nd ed. Bethesda, MD: AABB; 2020.
Luban NL, Strauss RG, Hume HA. Commentary on the safety of red cells preserved in extended-storage media for neonatal transfusions. Transfusion. 1991;31:229-35.
Strauss RG, Burmeister LF, Johnson K, James T, Miller J, Cordle DG, et al. AS-1 red cells for neonatal transfusions: a randomized trial assessing donor exposure and safety. Transfusion. 1996;36:873-8.
Strauss RG, Burmeister LF, Johnson K, Cress G, Cordle D. Feasibility and safety of AS-3 red blood cells for neonatal transfusions. J Pediatr. 2000;136:215-9.
Luban NL. Neonatal red blood cell transfusions. Curr Opin Hematol. 2002;9:533-6.
Karam O, Tucci M, Bateman ST, Ducruet T, Spinella PC, Randolph AG, et al. Association between length of storage of red blood cell units and outcome of critically ill children: a prospective observational study. Crit Care. 2010;14:R57.
Gauvin F, Spinella PC, Lacroix J, Choker G, Ducruet T, Karam O, et al. Association between length of storage of transfused red blood cells and multiple organ dysfunction syndrome in pediatric intensive care patients. Transfusion. 2010;50:1902-13.
Vraets A, Lin Y, Callum JL. Transfusion-associated hyperkalemia. Transfus Med Rev. 2011;25:184-96.
Zeller MP, Barty R, Aandahl A, Apelseth TO, Callum J, Dunbar NM, et al. An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study. Transfusion. 2017;57:2329-37.
Recommendations on the use of group O red blood cells. Bethesda, MD; AABB Association Bulletin #19-02. June 26, 2019. https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab19-02.pdf; last accessed July 31, 2020.
Weisberg SP, Staley EM, Williams LA 3rd, Pham HP, Bachegowda LS, Cheng YH, et al. Survey on transfusion-transmitted cytomegalovirus and cytomegalovirus disease mitigation. Arch Pathol Lab Med. 2017;141:1705-11.
Strauss RG. Optimal prevention of transfusion-transmitted cytomegalovirus (TTCMV) infection by modern leukocyte reduction alone: CMV sero/antibody-negative donors needed only for leukocyte products. Transfusion. 2016;56:1921-4.
Jacquot C, Mo YD, Luban NLC. New approaches and trials in pediatric transfusion medicine. Hematol Oncol Clin North Am. 2019;33:507-20.
Goodrich RP, Segatchian J. Special considerations for the use of pathogen reduced blood components in pediatric patients: an overview. Transfus Apher Sci. 2018;57:374-7.
Lu W, Delaney M, Flegel WA, Ness P, Ratcliffe N, Triulzi DJ, et al. How do you… decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service? Transfusion. 2020;60:675-81.
Schulz WL, McPadden J, Gehrie EA, Bahar B, Gokhale A, Ross R, et al. Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets. J Pediatr. 2019;209:220-5.
Lozano M, Heddle N, Williamson LM, Wang G, AuBuchon JP, Dumont LJ, et al. Practices associated with ABO-incompatible platelet transfusions: a BEST collaborative international survey. Transfusion. 2010;50:1743-8.
Steinbicker AU, Wittenmeier E, Goobie SM. Pediatric non-red cell blood product transfusion practices: what's the evidence to guide transfusion of the 'yellow' blood products? Curr Opin Anaesthesiol. 2020;33:259-67.
Josephson CD, Castillejo MI, Grima K, Hillyer CD. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci. 2010;42:83-8.
Malvik N, Leon J, Schlueter AJ, Wu C, Knudson CM. ABO-incompatible platelets are associated with increased transfusion reaction rates. Transfusion. 2020;60:285-93.
Yazer MH, Seheult J, Kleinman S, Sloan SR, Spinella PC. Who's afraid of incompatible plasma? A balanced approach to the safe transfusion of blood products containing ABO-incompatible plasma. Transfusion. 2018;58:532-8.
Goel R, Josephson CD, Patel EU, Petersen MR, Packman Z, Gehrie E, et al. Individual- and hospital-level correlates of red blood cell, platelet, and plasma transfusions among hospitalized children and neonates: a nationally representative study in the United States. Transfusion. 2020;60:1700-12.